Key Takeaways Novo Nordisk and its partner reported phase II data for UBT251 in Chinese patients with type II diabetes.UBT251 showed up to a 2.16% HbA1c reduction and 9.8% weight loss, outperforming semaglutide and placebo.Novo Nordisk plans a global phase II in 2026, while its partner prepares for phase III trials in China.Novo Nordisk (NVO) and its partner, The United Laboratories International Holdings Limited ("TUL"), jointly announced top-line data from a phase II study in China, evaluating UBT251, a n ...